Eculizumab
Back to Test Catalogue
Eculizumab (Soliris) – Free, Plasma
Test ID: ECULISO P
Test
Method
ELISA
Report Includes
Specimens
Plasma
Clinical Utility
Eculizumab is an anti-C5 monoclonal antibody that blocks the terminal complement activation pathway. This medication is mainly used to treat diseases related to overactivation of the alternative complement pathway, such as paroxysmal nocturnal hemoglobinuria, membranoproliferative glomerulonephritis and atypical hemolytic uremic syndrome. The Eculizumab assay makes it possible to determine the concentration of free plasma Eculizumab by ELISA method.
Test Version
9-Sep-2025
Specimen
Specimens
Plasma
Collection Containers
Blue top (3.2% buffered citrate)
Sample Volume
2.0 mL
Collection & Handling
Collection Instructions
Collect trough specimen prior to dose.
Handling Information
Prepare double-spun plasma within 2 hours of collection and transfer to polypropylene transfer vial. Store and send frozen.
Stability
| Refrigerated | 4 hours |
|---|---|
| Frozen | 7 days |
Additional Stability Information
90 days at - 70 ºC
Test Version
9-Sep-2025
Performance / Interpretation
Method
ELISA
Turnaround Time
25 days
Results
| Name | Units | Reference Range | Conversion Factor | |
|---|---|---|---|---|
| Eculizumab level | μg/mL |
|
||
Test Version
9-Sep-2025
Interface / Setup
Test Version
9-Sep-2025